Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...
Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...
Hosted on MSN4h
Here's Why Pfizer (PFE) is a Strong Momentum StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback